Risk of heart failure with dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials

Int J Cardiol. 2016 Jun 1:212:203-5. doi: 10.1016/j.ijcard.2016.03.016. Epub 2016 Mar 19.

¹ Department of Medicine, University of Massachusetts Medical School, Worcester, MA, USA. Electronic address: amartya.kundu@umassmemorial.org.
² Division of Cardiovascular Medicine, University of Utah, Salt Lake City, UT, USA.
³ Department of Medicine, Interfaith Medical Center, Brooklyn, NY, USA.
⁴ Department of Medicine, University of Massachusetts Medical School, Worcester, MA, USA.
⁵ Division of Cardiology, St Luke's-Roosevelt Hospital of the Mount Sinai Health System, New York, NY, USA.
⁶ Department of Medicine, Division of Cardiology, University of Massachusetts Medical School, Worcester, MA, USA.

No abstract available

Keywords: Alogliptin; Diabetes mellitus; Dipeptidyl peptidase-4 inhibitors; Heart failure; Saxagliptin; Sitagliptin.

Publication types